EUCTR2022-002348-33-PT进行中（未招募）1 期
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 446
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Previous participation in Study A35-004 (PHOENIX), including completion of the randomized-controlled phase through Week 48 (this timepoint may be upcoming at the time of screening). Participants who do not complete randomized-controlled phase through Week 48 for medical reasons may be included on a case-by-case basis, in consultation with the sponsor;
- •2. Capable of providing informed consent;
- •3. Capable and willing to follow trial procedures including visits to the trial clinic, remote visits, and survival status reporting requirements;
- •4. Women of childbearing potential (WOCBP; e.g., not post-menopausal for at least one year or surgically sterilea must agree to use adequate birth controlb for the duration of the trial and 3 months after the last dose of AMX0035;
- •a. 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •b. Acceptable contraception methods for use in this trial are:
- •- Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants;
- •- Barier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm);
- •- Intrauterine device (IUD);
- •- Abstinence (no heterosexual sex);
- •- Unique partner who is surgically sterile (men) or not of childbearing potential (female).
- •5. Women must not be pregnant or planning to become pregnant for the duration of the trial and 3 months after last dose of AMX0035;
- •6. Men must agree to practice contraception for the duration of the trial and for at least 3 months after last dose of AMX0035;
- •7. Men must not plan to father a child or to provide sperm for donation for the duration of the trial and 3 months after the last dose of AMX0035;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 286
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 160
排除标准
- •1. History of known allergy to phenyl butyrate or bile salts;
- •2. Abnormal liver function defined as bilirubin levels and/or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 5 times the upper limit of the normal (obtained within 12 weeks from first dose);
- •3. Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 normal (obtained within 12 weeks from first dose);
- •4. Pregnant women or women currently breastfeeding;
- •5. Current severe biliary disease which may result in the Investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gangrene of the gallbladder, abscess of the gallbladder;
- •6. History of Class III/IV heart failure (per New York Heart Association – NYHA);
- •7. Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Investigator clinical judgment;
- •8. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, according to Investigator judgment;
- •9. Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, severe laboratory test anomaly or clinically significant electrocardiogram [ECG] changes) that would pose a risk to the participant if he/she were to participate in the trial, according to Investigator judgment;
- •10. Currently enrolled in another trial (excluding Study A35-004 (PHOENIX)) involving use of an investigational therapy (or within 5 plasma half-lives) prior to first dose at Baseline Visit;
- •11. Implantation of Diaphragm Pacing System (DPS);
- •12. Currently or previously treated within the last 30 days (or 5 half-lives, whichever is longer) from first dose at the Baseline Visit or planned exposure during the treatment period to any prohibited medications listed in Section 6.7 of the protocol.
研究者
相似试验
进行中（未招募）
1 期
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)ALS (amyotrophic lateral sclerosis)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002348-33-ESAmylyx Pharmaceuticals Inc.600
招募中
3 期
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)Disease of nerve cells that control musclesNeurodegenerative syndrome10029317NL-OMON53858Amylyx Pharmaceuticals Inc.25
进行中（未招募）
1 期
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-0ALS (amyotrophic lateral sclerosis)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002348-33-NLAmylyx Pharmaceuticals Inc.446
已完成
3 期
A Phase III Open Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS studymuscular dystrophyNeuromuscular disease10028302NL-OMON48973Santhera Pharmaceuticals (Switzerland),11
已完成
3 期
This is an open-label, single arm (uncontrolled) study in subjects suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.CTRI/2011/04/001664ovartis Healthcare Private Limited100